Russell Investments Group
NKTR icon

Russell Investments Group’s Nektar Therapeutics NKTR Stock Holding History

Russell Investments Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.22M Sell
89,099
-17,149
-16% -$1.25M 0.01% 1366
2026
Q1 		$7.64M Buy
106,248
+20,582
+24% +$1.17M 0.01% 1093
2025
Q4 		$3.62M Buy
85,666
+68,617
+402% +$3.84M ﹤0.01% 1529
2025
Q3 		$970K Buy
17,049
+12,011
+238% +$398K ﹤0.01% 2216
2025
Q2 		$130K Buy
5,038
+13
+0.3% +$146 ﹤0.01% 2758
2025
Q1 		$51.3K Buy
5,025
+503
+11% +$6.57K ﹤0.01% 2904
2024
Q4 		$63.1K Sell
4,522
-1,441
-24% -$25.4K ﹤0.01% 2774
2024
Q3 		$116K Sell
5,963
-17
-0.3% -$324 ﹤0.01% 2619
2024
Q2 		$111K Buy
5,980
+484
+9% +$10.2K ﹤0.01% 2608
2024
Q1 		$77K Sell
5,496
-2,022
-27% -$21.2K ﹤0.01% 2607
2023
Q4 		$63.7K Sell
7,518
-3,061
-29% -$23.2K ﹤0.01% 2614
2023
Q3 		$94.5K Sell
10,579
-115
-1% -$1.11K ﹤0.01% 2634
2023
Q2 		$92.3K Hold
10,694
– – ﹤0.01% 2620
2023
Q1 		$113K Sell
10,694
-179
-2% -$5.42K ﹤0.01% 2567
2022
Q4 		$369K Buy
10,873
+5,334
+96% +$258K ﹤0.01% 2390
2022
Q3 		$264K Buy
5,539
+5,307
+2,288% +$316K ﹤0.01% 2469
2022
Q2 		$13K Sell
232
-582
-71% -$36.7K ﹤0.01% 2834
2022
Q1 		$64K Sell
814
-141
-15% -$20.9K ﹤0.01% 2612
2021
Q4 		$193K Sell
955
-321
-25% -$69.6K ﹤0.01% 2723
2021
Q3 		$343K Sell
1,276
-92
-7% -$22.1K ﹤0.01% 2604
2021
Q2 		$351K Sell
1,368
-681
-33% -$188K ﹤0.01% 2728
2021
Q1 		$613K Sell
2,049
-925
-31% -$288K ﹤0.01% 2443
2020
Q4 		$762K Sell
2,974
-83
-3% -$21.4K ﹤0.01% 2243
2020
Q3 		$759K Sell
3,057
-321
-10% -$101K ﹤0.01% 2196
2020
Q2 		$1.17M Buy
3,378
+3,306
+4,592% +$1.03M ﹤0.01% 1962
2020
Q1 		$19K Buy
72
+51
+243% +$15.8K ﹤0.01% 2956
2019
Q4 		$6K Sell
21
-239
-92% -$69.3K ﹤0.01% 3060
2019
Q3 		$70K Hold
260
– – ﹤0.01% 2892
2019
Q2 		$136K Hold
260
– – ﹤0.01% 2588
2019
Q1 		$128K Buy
260
+22
+9% +$13K ﹤0.01% 2698
2018
Q4 		$120K Sell
238
-97
-29% -$58.6K ﹤0.01% 2699
2018
Q3 		$305K Sell
335
-2,861
-90% -$2.44M ﹤0.01% 2556
2018
Q2 		$2.34M Sell
3,196
-1,367
-30% -$1.58M ﹤0.01% 1688
2018
Q1 		$7.26M Sell
4,563
-3,065
-40% -$3.95M 0.01% 1152
2017
Q4 		$6.92M Sell
7,628
-836
-10% -$494K 0.01% 1160
2017
Q3 		$3.05M Sell
8,464
-350
-4% -$109K 0.01% 1539
2017
Q2 		$2.58M Buy
8,814
+2,750
+45% +$795K ﹤0.01% 1587
2017
Q1 		$2.13M Buy
6,064
+711
+13% +$160K ﹤0.01% 1726
2016
Q4 		$979K Buy
+5,353
New +$1.09M ﹤0.01% 2180

Other funds holding NKTR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group's NKTR Position: Q2 2026 in Review

Russell Investments Group reduced its Nektar Therapeutics (NKTR) stake by 16% in Q2 2026, selling an estimated $1.25M and leaving 89,099 shares worth $6.22M. The position accounts for 0.01% of the portfolio, ranked #1366.

Russell Investments Group first reported a position in NKTR in Q4 2016 and has held it in 39 quarters since. The position peaked at $7.64M in Q1 2026. 70 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Russell Investments Group held 89,099 shares of Nektar Therapeutics worth $6.22M as of Q2 2026.
  • Russell Investments Group sold 17,149 Nektar Therapeutics shares in Q2 2026, an estimated $1.25M.
  • Nektar Therapeutics made up 0.01% of Russell Investments Group's portfolio in Q2 2026, its #1366 holding.
  • Russell Investments Group first reported a position in Nektar Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • Russell Investments Group's Nektar Therapeutics position peaked at $7.64M in Q1 2026.
  • 70 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.